Infinity Pharmaceuticals Investor Relations Material
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on developing novel medicines for people with cancer. The Company's pipeline includes DVC-1201, an anti-CD20 monoclonal antibody for the treatment of B-cell lymphoma and follicular lymphoma; DVC-1202, an anti-IGF-1R monoclonal antibody for the treatment of colorectal cancer; and is also developing an oral pan-Immunoglobulin product candidate that targets certain cancers
Key slides for Infinity Pharmaceuticals Inc
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
🇺🇸 United States